• 1
    Alter M. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6S9.
  • 2
    Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc of the Natl Acad Sci U S A 2010; 107: 1475714762.
  • 3
    Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56( Suppl 1):S88-S100.
  • 4
    Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962973.
  • 5
    Lucas M, Ulsenheimer A, Pfafferot K, Heeg MHJ, Gaudieri S, Grüner N, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One 2007; 2: e649.
  • 6
    Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J virol 2004; 78: 15751581.
  • 7
    Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315324.
  • 8
    Pape G, Gerlach T, Diepolder H, Grüner N, Jung MC, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J viral hepat 1999; 6: 3640.
  • 9
    Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc of the Natl Acad Sci U S A 2007; 104: 6025.
  • 10
    Choo Q, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc of the Natl Acad Sci U S A 1994; 91: 1294.
  • 11
    Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961966.
  • 12
    Meunier J-C, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204: 11861190.
  • 13
    Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28: 63676373.
  • 14
    Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, et al. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 1998; 273: 32088.
  • 15
    Sominskaya I, Alekseeva E, Skrastina D, Mokhonov V, Starodubova E, Jansons J, et al. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol immunol 2006; 43: 19411952.
  • 16
    Garrone P, Fluckiger A-C, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3: 94ra71.
  • 17
    McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178180.
  • 18
    Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N Biotechnol 2009; 25: 226234.
  • 19
    Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2007; 14: 2527.
  • 20
    Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 2012; 109: 62056210.
  • 21
    Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174: 1168.
  • 22
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791796.
  • 23
    Gottwein JM, Scheel TKH, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49: 364377.
  • 24
    Bartosch B, Dubuisson J, Cosset F-L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633642.
  • 25
    Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005; 41: 265274.
  • 26
    Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474: S18S19.
  • 27
    Edwards VC, Tarr AW, Urbanowicz RA, Ball JK. The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012; 93: 119.
  • 28
    Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 2001; 75: 21302141.
  • 29
    Michel ML, Mancini M, Sobczak E, Favier V, Guetard D, Bahraoui EM, et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV–hepatitis B surface antigen particles. Proc Natl Acad Sci USA 1988; 85: 7957.
  • 30
    Keck Z-Y, Li T-K, Xia J, Gal-Tanamy M, Olson O, Li SH, et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 2008; 82: 60616066.
  • 31
    Meunier J-C, Russell RS, Goossens V, Priem S, Walter H, Depla E, et al. Isolation and Characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J Virol 2007; 82: 966973.
  • 32
    Leroux-Roels G, Batens A-H, Desombere I, Van Den Steen B, Vander Stichele C, Maertens G, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005; 1: 6165.
  • 33
    Keck ZY, Sung VMH, Perkins S, Rowe J, Paul S, Liang TJ, et al. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J virol 2004; 78: 72577263.
  • 34
    Brazzoli M, Helenius A, Foung SKH, Houghton M, Abrignani S, Merola M. Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology 2005; 332: 438453.
  • 35
    Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004; 22: 30803086.
  • 36
    Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JAR, Priem S, et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 2011; 204: 837844.
  • 37
    Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008; 135: 17191728.e1.
  • 38
    Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 1994; 68: 61476160.
  • 39
    Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010; 84: 1015910168.
  • 40
    Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007; 25: 77737784.
  • 41
    Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8: 379386.